BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 25059094)

  • 21. Neuropsychiatric Impact of Androgen Deprivation Therapy in Patients with Prostate Cancer: Current Evidence and Recommendations for the Clinician.
    Siebert AL; Lapping-Carr L; Morgans AK
    Eur Urol Focus; 2020 Nov; 6(6):1170-1179. PubMed ID: 32690473
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Depressive symptomatology in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison.
    Lee M; Jim HS; Fishman M; Zachariah B; Heysek R; Biagioli M; Jacobsen PB
    Psychooncology; 2015 Apr; 24(4):472-7. PubMed ID: 24924331
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psychological effects of androgen-deprivation therapy on men with prostate cancer and their partners.
    Donovan KA; Walker LM; Wassersug RJ; Thompson LM; Robinson JW
    Cancer; 2015 Dec; 121(24):4286-99. PubMed ID: 26372364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quality of life in prostate cancer patients taking androgen deprivation therapy.
    Dacal K; Sereika SM; Greenspan SL
    J Am Geriatr Soc; 2006 Jan; 54(1):85-90. PubMed ID: 16420202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of masculine identity, marital affection, and sexual bother in men with localized prostate cancer.
    Zaider T; Manne S; Nelson C; Mulhall J; Kissane D
    J Sex Med; 2012 Oct; 9(10):2724-32. PubMed ID: 22989267
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Initial results of a randomized phase III trial of high dose image guided radiation with or without androgen deprivation therapy for intermediate-risk prostate cancer.
    Vargas CE; Alam NB; Terk M; Niska JR; Cesaretti J; Swartz D; Vashi A; Kasraeian A; West CS; Blasser M; Moore C
    Cancer Treat Res Commun; 2019; 19():100119. PubMed ID: 30772671
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of endothelial dysfunction by flow-mediated dilatation in men on long-term androgen deprivation therapy for prostate cancer.
    Gilbert SE; Tew GA; Bourke L; Winter EM; Rosario DJ
    Exp Physiol; 2013 Sep; 98(9):1401-10. PubMed ID: 23666791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cognitive and neurobehavioral symptoms in patients with non-metastatic prostate cancer treated with androgen deprivation therapy or observation: A mixed methods study.
    Wu LM; Tanenbaum ML; Dijkers MP; Amidi A; Hall SJ; Penedo FJ; Diefenbach MA
    Soc Sci Med; 2016 May; 156():80-9. PubMed ID: 27019142
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of androgen deprivation therapy on sexual function.
    Mazzola CR; Mulhall JP
    Asian J Androl; 2012 Mar; 14(2):198-203. PubMed ID: 22231298
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer.
    Morgans AK; Chen YH; Sweeney CJ; Jarrard DF; Plimack ER; Gartrell BA; Carducci MA; Hussain M; Garcia JA; Cella D; DiPaola RS; Patrick-Miller LJ
    J Clin Oncol; 2018 Apr; 36(11):1088-1095. PubMed ID: 29522362
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of walking exercise in promoting cognitive-psychosocial functions in men with prostate cancer receiving androgen deprivation therapy.
    Lee CE; Kilgour A; Lau YK
    BMC Cancer; 2012 Jul; 12():324. PubMed ID: 22846379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of depression, anxiety and quality of life in patients with prostate cancer receiving androgen deprivation therapy.
    Chipperfield K; Fletcher J; Millar J; Brooker J; Smith R; Frydenberg M; Burney S
    Psychooncology; 2013 Oct; 22(10):2169-76. PubMed ID: 23483679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Perceptions of physically active men with prostate cancer on the role of physical activity in maintaining their quality of life: possible influence of androgen deprivation therapy.
    Keogh JW; Patel A; MacLeod RD; Masters J
    Psychooncology; 2013 Dec; 22(12):2869-75. PubMed ID: 23904113
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer.
    DiBlasio CJ; Malcolm JB; Derweesh IH; Womack JH; Kincade MC; Mancini JG; Ogles ML; Lamar KD; Patterson AL; Wake RW
    BJU Int; 2008 Jul; 102(1):39-43. PubMed ID: 18294309
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quality of life effects of androgen deprivation therapy in a prostate cancer cohort in New Zealand: can we minimize effects using a stratification based on the aldo-keto reductase family 1, member C3 rs12529 gene polymorphism?
    Karunasinghe N; Zhu Y; Han DY; Lange K; Zhu S; Wang A; Ellett S; Masters J; Goudie M; Keogh J; Benjamin B; Holmes M; Ferguson LR
    BMC Urol; 2016 Aug; 16(1):48. PubMed ID: 27485119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues.
    Gomella LG
    BJU Int; 2007 Jan; 99 Suppl 1():25-9; discussion 30. PubMed ID: 17229166
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Symptom burden profiles in men with advanced prostate cancer undergoing androgen deprivation therapy.
    Noriega Esquives B; Lee TK; Moreno PI; Fox RS; Yanez B; Miller GE; Estabrook R; Begale MJ; Flury SC; Perry K; Kundu SD; Penedo FJ
    J Behav Med; 2022 Jun; 45(3):366-377. PubMed ID: 35107655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy.
    Potosky AL; Reeve BB; Clegg LX; Hoffman RM; Stephenson RA; Albertsen PC; Gilliland FD; Stanford JL
    J Natl Cancer Inst; 2002 Mar; 94(6):430-7. PubMed ID: 11904315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of age on quality-of-life outcomes after treatment for localized prostate cancer.
    Hampson LA; Cowan JE; Zhao S; Carroll PR; Cooperberg MR
    Eur Urol; 2015 Sep; 68(3):480-6. PubMed ID: 25656807
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Psychological distress in men with prostate cancer receiving adjuvant androgen-deprivation therapy.
    Saini A; Berruti A; Cracco C; Sguazzotti E; Porpiglia F; Russo L; Bertaglia V; Picci RL; Negro M; Tosco A; Campagna S; Scarpa RM; Dogliotti L; Furlan PM; Ostacoli L
    Urol Oncol; 2013 Apr; 31(3):352-8. PubMed ID: 21803612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.